NCT01930006View on ClinicalTrials.gov

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions
Advanced Malignancies
Interventions
DRUG

MGCD265

Trial Locations (1)

66212

Vince & Associates Clinical Research, Inc., Overland Park

Sponsors
All Listed Sponsors
lead

Mirati Therapeutics Inc.

INDUSTRY

NCT01930006 - Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State | Biotech Hunter | Biotech Hunter